tiprankstipranks
Trending News
More News >
Bayer (DE:BAYN)
XETRA:BAYN

Bayer (BAYN) AI Stock Analysis

Compare
743 Followers

Top Page

DE

Bayer

(XETRA:BAYN)

Rating:62Neutral
Price Target:
€28.00
▲(3.78%Upside)
Bayer's overall stock score is primarily influenced by positive cash flow management and technical indicators suggesting moderate bullish momentum. However, challenges in profitability and a negative P/E ratio weigh down the score. The insider purchase by a board member provides a positive outlook, enhancing investor confidence.
Positive Factors
Cash Flow
The company has implemented measures to maximize cash flow generation, which is crucial given the high level of debt.
Financial Performance
FY-24 FCF came in at €3.1bn ahead of guidance. Net debt at €32.6bn (FY-23: 34.5bn), which is good news.
Negative Factors
Earnings
Bayer underperformed significantly due to weaker-than-expected agrochemicals performance and questions on long-term pharma growth.
Generic Competition
The Crop Science business is facing a broader-than-expected generics impact, affecting the company's overall performance.
Litigation
Ongoing litigation related to glyphosate is creating uncertainty for investors, with 67,000 cases still unsettled.
Market Conditions
Bayer is cautious for FY-25 and the wide margin range of 300bps is explained by the uncertainty around the generic competition for Xarelto in Europe.

Bayer (BAYN) vs. iShares MSCI Germany ETF (EWG)

Bayer Business Overview & Revenue Model

Company DescriptionBayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
How the Company Makes MoneyBayer makes money through its three main divisions: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division generates revenue through the sale of prescription drugs, which are often protected by patents, allowing for premium pricing and a significant share of the company's income. The Consumer Health division provides over-the-counter products available to consumers worldwide, contributing to a steady stream of revenue through well-known brands. The Crop Science division earns money by selling seeds, crop protection products, and digital farming solutions that help farmers increase crop yields and efficiency. Revenue is further supported by strategic partnerships, collaborations, and acquisitions that enhance Bayer's product offerings and market reach.

Bayer Financial Statement Overview

Summary
Bayer's financial performance is hindered by weak profitability and high leverage, as evidenced by negative net income and a high debt-to-equity ratio. However, strong gross margins and positive cash flow management provide some stability.
Income Statement
60
Neutral
Bayer's income statement shows weak profitability with net losses in recent years. The TTM (Trailing-Twelve-Months) gross profit margin is 54.0%, which is strong, but the net profit margin is negative due to the significant net loss. Revenue growth has been inconsistent, with a recent decline from 2023 to 2024. EBIT and EBITDA margins are also under pressure, indicating challenges in operational efficiency.
Balance Sheet
55
Neutral
The balance sheet reflects a high debt-to-equity ratio, signaling significant leverage, which poses risk in times of financial stress. The equity ratio stands at 29.7%, indicating moderate equity financing. Return on Equity (ROE) is negative due to net losses, demonstrating challenges in generating returns for shareholders.
Cash Flow
70
Positive
Bayer's cash flow statement shows resilience with a positive operating cash flow and a decent free cash flow. The free cash flow has grown compared to the previous period, highlighting effective cash management. The operating cash flow to net income ratio is favorable, suggesting robust cash generation despite accounting losses.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue46.58B46.61B47.64B50.74B44.08B41.40B
Gross Profit25.15B25.34B27.89B30.87B27.27B22.26B
EBITDA8.08B8.81B4.21B10.44B6.97B-11.48B
Net Income-3.25B-2.55B-2.94B4.15B1.00B-15.56B
Balance Sheet
Total Assets109.18B110.85B116.26B124.88B120.24B117.05B
Cash, Cash Equivalents and Short-Term Investments5.38B8.09B10.59B10.15B7.74B11.88B
Total Debt39.38B40.81B44.79B41.32B39.53B41.55B
Total Liabilities76.60B78.81B83.18B85.95B87.07B86.35B
Stockholders Equity32.45B31.91B32.93B38.77B33.02B30.52B
Cash Flow
Free Cash Flow5.27B4.59B2.37B4.14B2.48B2.48B
Operating Cash Flow7.99B7.37B5.12B7.09B5.09B4.90B
Investing Cash Flow22.00M164.00M-4.01B-2.38B855.00M-4.07B
Financing Cash Flow-9.10B-7.18B-679.00M-4.22B-5.64B423.00M

Bayer Technical Analysis

Technical Analysis Sentiment
Positive
Last Price26.98
Price Trends
50DMA
24.69
Positive
100DMA
23.40
Positive
200DMA
23.14
Positive
Market Momentum
MACD
0.57
Positive
RSI
61.46
Neutral
STOCH
35.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BAYN, the sentiment is Positive. The current price of 26.98 is above the 20-day moving average (MA) of 26.63, above the 50-day MA of 24.69, and above the 200-day MA of 23.14, indicating a bullish trend. The MACD of 0.57 indicates Positive momentum. The RSI at 61.46 is Neutral, neither overbought nor oversold. The STOCH value of 35.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:BAYN.

Bayer Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
€26.50B-9.56%0.36%-0.92%-4.30%
46
Neutral
C$190.36M-4.25-8.56%3.09%13.53%-1.76%
€14.17B22.924.37%2.98%
€23.75B56.856.28%2.04%
€48.98B17.389.74%1.97%
€13.80B127.953.55%0.41%
$61.33B27.3811.14%1.80%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:BAYN
Bayer
26.98
0.93
3.57%
GB:0H9X
Fresenius Medical Care AG & Co. KGaA
48.30
13.07
37.10%
GB:0OO9
Fresenius SE & Co. KGaA
42.59
14.51
51.67%
GB:0O14
Merck KGaA
112.65
-38.55
-25.50%
GB:0NIQ
Sartorius
177.00
3.73
2.15%
SEMHF
Siemens Healthineers AG
54.90
-2.38
-4.16%

Bayer Corporate Events

Business Operations and Strategy
Bayer Supervisory Board Member Purchases Company Shares
Positive
Apr 1, 2025

Bayer Aktiengesellschaft announced a transaction involving the purchase of shares by a member of its supervisory board, Kimberly Mathisen. This transaction, conducted at the Frankfurt Stock Exchange, reflects the board members’ commitment to buy Bayer AG shares, potentially signaling confidence in the company’s future performance.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 24, 2025